title: The politics of access to expensive drugs: INESSS and the innovative pharmaceutical industry.
abstract: The innovative pharmaceutical industry employs thousands of people in Quebec and so has the ability to exert strong political pressure; the public statements of Sanofi-Aventis concerning the provincial reimbursement of certain expensive drugs are an example. "Maintaining a dynamic biopharmaceutical industry" is one of four main axes of the drug policy of Quebec's ministry of health. However, this role of government should not take precedence over the efficient and equitable management of health resources. We defend the legitimate and responsible choice of the Institut national d'excellence en santé et en services sociaux du Québec (INESSS) to require an acceptable cost-effectiveness ratio from expensive new drugs.
authors: Sciences Humaines Appliquées; Bioéthique, Université de Montréal, Montréal, QC. david.hughes@umontreal.ca
authors: David
authors: D
authors: Hughes
mesh_terms: D016527:Drug Costs; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration; D006291:Health Policy; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration; D006801:Humans; D011057:Politics; D055553:Prescription Drugs / Q000191:economics / Q000600:supply & distribution*; D011792:Quebec
chemical_list: D055553:Prescription Drugs
references: J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605
references: 20384650
references: J Health Polit Policy Law. 2000 Dec;25(6):1083-120
references: 11142053
references: Europace. 2011 Mar;13(3):329-45
references: 21227948
references: Health Econ. 2010 Oct;19(10):1109-16
references: 20842680
references: Can J Public Health. 2005 Nov-Dec;96(6):454-8
references: 16350873
references: Hastings Cent Rep. 2006 Jul-Aug;36(4):22-35
references: 16898358
references: Can J Public Health. 2001 Jul-Aug;92(4):307-12
references: 11962119